Forbion funds line up pre-IPO stake in Braveheart Bio (BRVE)
Rhea-AI Filing Summary
Braveheart Bio, Inc. (BRVE) reports initial ownership by Forbion-related investment entities, each noted as a 10% owner. The positions include Series A Preferred Stock that is convertible into Common Stock on a one-for-4.38 basis and automatically converts into the stated numbers of Common shares immediately before the company’s initial public offering, with no expiration date. Reported holdings include both direct and indirect positions, and the reporting persons disclaim Section 16 beneficial ownership except to the extent of any pecuniary interest.
Positive
- None.
Negative
- None.
Insider Trade Summary
4 transactions reported
Mixed
4 txns
Insider
Forbion Growth Opportunities Fund III Cooperatief U.A., Forbion Growth III Management B.V., Forbion Ventures Fund VII Cooperatief U.A., Forbion Ventures VII Management B.V.
Role
10% Owner | 10% Owner | 10% Owner | 10% Owner
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Series A Preferred Stock F3, F1 | -- | -- | -- |
| holding | Series A Preferred Stock F3, F2 | -- | -- | -- |
| holding | Common Stock F1 | -- | -- | -- |
| holding | Common Stock F2 | -- | -- | -- |
Holdings After Transaction:
Series A Preferred Stock — 9,132,420 shares (Direct);
Series A Preferred Stock — 7,990,867 shares (Indirect, By Forbion Ventures Fund VII Cooperatief U.A.);
Common Stock — 588,126 shares (Direct);
Common Stock — 514,611 shares (Indirect, By Forbion Ventures Fund VII Cooperatief U.A.)
Footnotes (3)
- F1. Forbion Growth III Management B.V. ("Forbion Growth III Management") is the director of Forbion Growth Opportunities Fund III Cooperatief U.A. (the "Forbion Growth III") and may be deemed to have voting and dispositive power over the securities beneficially owned by the Forbion Growth III. Each of the Reporting Persons disclaims Section 16 beneficial ownership of such shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that any of the Reporting Persons are the beneficial owner of such shares for Section 16 or any other purpose.
- F2. Forbion Ventures VII Management B.V. ("Forbion VII Director") is the director of Forbion Ventures Fund VII Cooperatief U.A. (the "Forbion Ventures VII") and may be deemed to have voting and dispositive power over the securities beneficially owned by the Forbion Ventures VII. Each of the Reporting Persons disclaims Section 16 beneficial ownership of such shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that any of the Reporting Persons are the beneficial owner of such shares for Section 16 or any other purpose.
- F3. Each share of Series A Preferred Stock is convertible into Common Stock on a one-for-4.38 basis at the option of the holder, and will convert automatically immediately prior to the closing of the Issuer's initial public offering into the number of shares shown in column 3 without payment of consideration. The Series A Preferred Stock has no expiration date.
Key Figures
Underlying Common Shares (Series A, direct): 9,132,420 shares
Underlying Common Shares (Series A, indirect): 7,990,867 shares
Direct Common Stock: 588,126 shares
+2 more
5 metrics
Underlying Common Shares (Series A, direct)
9,132,420 shares
Common Stock underlying Series A Preferred Stock, direct ownership, as of 2026-08-05
Underlying Common Shares (Series A, indirect)
7,990,867 shares
Common Stock underlying Series A Preferred Stock, indirect ownership, as of 2026-08-05
Direct Common Stock
588,126 shares
Directly held Common Stock position, as of 2026-08-05
Indirect Common Stock
514,611 shares
Indirectly held Common Stock by Forbion Ventures Fund VII Cooperatief U.A., as of 2026-08-05
Conversion Ratio
1-for-4.38
Each share of Series A Preferred Stock converts into Common Stock on this basis
Key Terms
Series A Preferred Stock, disclaims Section 16 beneficial ownership, pecuniary interest, voting and dispositive power
4 terms
Series A Preferred Stock financial
"Each share of Series A Preferred Stock is convertible into Common Stock"
Series A preferred stock is a type of ownership share in a company that gives investors certain advantages, such as priority in receiving profits or getting their money back if the company is sold or goes bankrupt. It is often issued during early funding stages to attract investors by offering more security than common shares. This stock matters to investors because it provides a safer way to invest while still holding potential for future gains.
disclaims Section 16 beneficial ownership regulatory
"Each of the Reporting Persons disclaims Section 16 beneficial ownership of such shares"
pecuniary interest financial
"except to the extent of its pecuniary interest therein, if any"
voting and dispositive power financial
"may be deemed to have voting and dispositive power over the securities"
FAQ
What insider holdings are reported in BRVE’s Form 3 for Forbion entities?
The Form 3 reports Forbion entities holding Series A Preferred Stock and Common Stock, including both direct and indirect positions, establishing them as 10% owners of Braveheart Bio, Inc. These are initial ownership disclosures, not new buy or sell transactions.
What direct Common Stock holdings are reported for BRVE in this Form 3?
The filing shows direct ownership of 588,126 shares of Braveheart Bio Common Stock. This figure reflects shares held directly by a Forbion-related reporting person, separate from the Common shares underlying the Series A Preferred Stock positions.
What indirect Common Stock holdings are reported for BRVE by Forbion Ventures Fund VII?
The Form 3 reports 514,611 shares of Common Stock held indirectly, noted as held “By Forbion Ventures Fund VII Cooperatief U.A.”. These are attributed to the fund, with the management entity potentially having voting and dispositive power over the position.
When and how will BRVE’s Series A Preferred Stock convert to Common Stock?
Each share of Series A Preferred Stock is convertible into Common Stock on a one-for-4.38 basis at the holder’s option and will convert automatically immediately prior to the closing of the initial public offering into the reported numbers of Common shares, without payment of consideration.
Do the Forbion reporting persons claim full beneficial ownership of their BRVE holdings?
No. The reporting persons explicitly disclaim Section 16 beneficial ownership of the shares except to the extent of any pecuniary interest. The disclosures state this report is not an admission of beneficial ownership for Section 16 or any other purpose.
AI-generated analysis. How Rhea-AI works. Not financial advice.
